EGFR and cancer: We are optimistic that the combination of potent, selective inhibitors of ERBB mutants, together with inhibitors of other pathways involved in drug resistance or with immunotherapy, will ultimately lead to durable responses and perhaps cures for the hundreds of thousands of patients with ERBB-driven cancers.